July 12, 2018 - By Eugene Smith

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Logo


CONCERT PHARMACEUTICALS (NASDAQ:CNCE) institutional sentiment decreased to 1.37 in Q1 2018. Its down -1.25, from 2.62 in 2017Q4. The ratio is negative, as 63 investment managers started new or increased equity positions, while 46 sold and decreased their stakes in CONCERT PHARMACEUTICALS. The investment managers in our partner’s database now have: 16.64 million shares, up from 15.49 million shares in 2017Q4. Also, the number of investment managers holding CONCERT PHARMACEUTICALS in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 13 Reduced: 33 Increased: 34 New Position: 29.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $404.51 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 3.92 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

The stock increased 0.17% or $0.03 during the last trading session, reaching $17.29. About 11,947 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 41.24% since July 12, 2017 and is uptrending. It has outperformed by 28.67% the S&P500.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on August, 14. They expect $-0.62 earnings per share, down 6.90 % or $0.04 from last year’s $-0.58 per share. After $-0.19 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 226.32 % negative EPS growth.

Bvf Inc Il holds 4.49% of its portfolio in Concert Pharmaceuticals, Inc. for 1.93 million shares. Ghost Tree Capital Llc owns 350,000 shares or 1.62% of their US portfolio. Moreover, Ingalls & Snyder Llc has 1.48% invested in the company for 1.32 million shares. The New York-based Senzar Asset Management Llc has invested 1.44% in the stock. Knott David M, a New York-based fund reported 49,557 shares.

Since January 1, 0001, it had 0 buys, and 7 sales for $3.17 million activity.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Ratings Coverage

Ratings analysis reveals 100% of Concert Pharmaceuticals’s analysts are positive. Out of 2 Wall Street analysts rating Concert Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $25 while the high is $27.0. The stock’s average target of $26.50 is 53.27% above today’s ($17.29) share price. CNCE was included in 3 notes of analysts from March 2, 2018. The firm has “Buy” rating given on Friday, March 9 by Mizuho. H.C. Wainwright maintained the stock with “Buy” rating in Friday, May 4 report. The stock has “Buy” rating by H.C. Wainwright on Friday, March 2.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: